Recently, a number of novel genetic alterations have been identified that predispose
individuals to pituitary adenomas. Clinically relevant pituitary adenomas are relatively …

Pituitary adenomas (PAs) can be classified as non-secreting adenomas, somatotroph
adenomas, corticotroph adenomas, lactotroph adenomas, and thyrotroph adenomas …

While 95% of pituitary adenomas arise sporadically without a known inheritable
predisposing mutation, in about 5% of the cases they can arise in a familial setting, either …

Abstract Background Pancreatic neuroendocrine tumors (PNETs) represent a distinct
hypervascularized tumor entity, often diagnosed at metastatic stage. Therapeutic efficacy of …

Dysregulated metabolism is one of the key characteristics of cancer cells. The most
prominent alterations are present during regulation of cell respiration, which leads to a …

Pancreatic neuroendocrine neoplasms (pNENs) are a heterogeneous group of tumors
including well differentiated pancreatic neuroendocrine tumors (pNETs) and …

Abstract Introduction Neuroendocrine tumors (NETs) have proven to be appropriate
neoplasms for peptide receptor radionuclide therapy (PRRT), as the majority of these slow …

Surgical resection is the foundation for treatment of small bowel neuroendocrine tumors
(SBNETs). Guidelines for surgical management of SBNETs rely on retrospective data, which …

Neuroendocrine tumors (NETs) are a heterogeneous group of malignancies arising from
neural crest-derived cells throughout the body. The presentation and natural history of NETs …

Background and Objectives Neoadjuvant therapy plays an increasingly important role in
pancreatic neuroendocrine neoplasms (pNENs), but the systematic evaluation of its efficacy …